BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Elitra, whose assets were acquired by Merck in 2004, was an antimicrobial functional genomics company that focused on the identification, development and commercialization of novel antimicrobial compounds that target essential gene products of pathogenic organisms.
Elitra Phramaceuticals
San Diego, CA
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.